Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Traws Pharma (TRAW) Revenue (2016 - 2025)

Traws Pharma's Revenue history spans 14 years, with the latest figure at $2.7 million for Q2 2025.

  • Quarterly results put Revenue at $2.7 million for Q2 2025, up 4694.74% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (up 1134.51% YoY), and the annual figure for FY2025 was $2.8 million, up 1134.51%.
  • Revenue for Q2 2025 was $2.7 million at Traws Pharma, up from $57000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.7 million in Q2 2025 to a low of $56000.0 in Q1 2021.
  • The 5-year median for Revenue is $57000.0 (2021), against an average of $205222.2.
  • The sharpest move saw Revenue fell 13.64% in 2021, then skyrocketed 4694.74% in 2025.
  • Year by year, Revenue stood at $56000.0 in 2021, then changed by 0.0% to $56000.0 in 2022, then changed by 0.0% to $56000.0 in 2023, then changed by 0.0% to $56000.0 in 2024, then skyrocketed by 4780.36% to $2.7 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $2.7 million, $57000.0, and $56000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.